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Abstract
Background: Alcoholic hepatitis (AH) has the most severe presentation among alcohol-related liver diseases.
Corticosteroids are the most widely recommended treatment for severe AH. However, more innovative, refined
treatment measures are required because of its high mortality despite corticosteroid treatment. This study aims to
determine whether granulocyte colony stimulating factor (G-CSF) treatment increases short-term survival in patients
with severe AH refractory to corticosteroid treatment.
Methods/design: Patients with severe AH whose Maddrey’s discriminant function (MDF) score is ≥ 32 and who will
be treated with prednisolone (40 mg/day) for 1 week will be screened. Among them, 190 subjects with a partial
response (PR) (Lille score 0.16–0.56), and 78 subjects with a null response (NR) (Lille score ≥ 0.56) will be enrolled.
Subjects with PR will be randomized to steroid plus placebo or steroid plus 12 G-CSF injections (5 μg/kg/day for 5
days followed by every 3 days) at a ratio of 1:1. Subjects with a NR will be randomized to the placebo or G-CSF
group (1:1). Study subjects in the PR group will be treated with prednisolone for 28 days followed by dose tapering
for an additional 2 weeks. The primary endpoint is the 2-month survival rate in the NR group and the 6-month
survival rate in the PR group. Child–Turcotte–Pugh, model for end-stage liver disease score, and the change in the
proportion of peripheral circulating CD34-positive cells will be analyzed as risk factors for mortality. Preliminary
safety data for the initial 10 study subjects enrolled in the PR study will be assessed to determine whether the PR
study would be continued, according to the G-CSF-mobilized, peripheral-blood stem cell donor assessment
protocol of the National Marrow Donor Program.
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Discussion: We hypothesized that G-CSF would prolong short-term survival of patients with severe AH refractory to
corticosteroid treatment. This is a proof-of-concept trial designed to assess the efficacy of Lille-score-guided G-CSF
treatment. This trial is also designed to identify a special subgroup in whom G-CSF rescue treatment would
improve liver function and prolong survival.
Trial registration: ClinicalTrials.gov, NCT02442180. Prospectively registered on 13 May 2015.
Keywords: Alcoholic hepatitis, Prednisolone, G-CSF, Discriminant function,
Background
Over several decades, South Korea has ranked as one of
the developed countries with the largest consumption of
alcohol in the world [1, 2]. Alcohol-related liver disease
is a broad-spectrum disease entity, including hepatic
steatosis, hepatitis, cirrhosis, and hepatocellular carcin-
oma, as one individual can have various progressive
stages of liver damage. Among them, alcoholic hepatitis
has the worst prognosis, with short-term mortality of
40% within 1 month of onset [3–5].
Severe alcoholic hepatitis (AH) is defined as Maddrey’s
Discriminant Function (MDF) score ≥ 32 points or when
the patient also had hepatic encephalopathy, which has a
very poor prognosis and 28-day mortality of 30–50% if
not treated [6, 7]. Severe AH has a higher short-term
mortality rate than any other liver disease, including
viral hepatitis and nonalcoholic fatty liver disease. None-
theless, survival has not notably improved in severe AH,
despite advances in medicine [8].
Corticosteroids (prednisolone 40 mg/day, 28 days) are
the most widely recommended treatment for severe AH.
Corticosteroid treatment is indicated for patients with
severe AH who are expected to have a very poor prog-
nosis, with a MDF score ≥ 32 points and model for
end-stage liver disease (MELD) score > 21 points or hep-
atic encephalopathy [9, 10]. However, corticosteroids
cannot be used when the patient also has upper gastro-
intestinal bleeding, renal failure, pancreatitis, or an un-
controlled infection [11, 12]. A recent meta-analysis of
individual patient data from five randomized controlled
trials demonstrated that the 28-day survival rate was sig-
nificantly higher in the steroid group than in the placebo
group (80.0% vs. 65.7%, P < 0.001). Thus, corticosteroids
are a standard treatment in selected patients with AH
and a MDF score ≥ 32 [7]. However, early recognition of
non-response to corticosteroids (40% of the patients
with severe AH who receive corticosteroid treatment) is
essential to minimize unnecessary exposure to cortico-
steroids [13]. The short-term mortality of 20% despite
corticosteroid treatment still desperately requires more
advanced treatment measures [7].
To overcome the difficulties of exploring rescue ther-
apies for steroid non-responders, several clinical trials
have been conducted to increase the survival rate using
granulocyte colony stimulating factor (G-CSF) in pa-
tients with severe AH [14, 15]. Although the standard
treatment with corticosteroids may reduce necroinflam-
mation in patients with AH, mortality remains strikingly
high [16]. Therefore, if G-CSF treatment facilitates liver
regeneration and enhances neutrophil function in pa-
tients with severe AH taking corticosteroids [17–19], it
is expected to significantly improve the current standard
treatment strategy.
The aim of this study is to test whether it is possible
to increase the 2-month survival rate (null responder to
steroids) or the 6-month survival rate (partial responder
to steroids) using G-CSF treatment in patients with se-




The aim of this study is to establish proof of concept
whether patients with severe AH (MDF score ≥ 32)
would benefit from G-CSF rescue therapy. The primary
aim is to evaluate whether G-CSF treatment prolongs
6-month overall survival (OS) of patients with a partial
response (PR) to steroids and 2-month OS of patients
with a null response (NR) to steroids. Partial responders
(0.16 < Lille score < 0.56) or null responders (Lille score ≥
0.56) are identified based on the Lille score after 1 week
of corticosteroid treatment (40 mg daily prednisolone
dose). The secondary aims are to identify the risk factors
in relation to mortality and the predictive factors associ-
ated with responses to standard corticosteroid treatment
or rescue G-CSF therapy. Pre-allocation and
post-allocation risk factors related to mortality include
age, sex, the presence of ascites, infection, gastrointes-
tinal bleeding, daily dose of alcohol consumed, the pres-
ence and period of abstinence, white blood cell count,
hemoglobin, hematocrit, high sensitivity C-reactive pro-
tein, blood urea nitrogen, creatinine, aspartate amino-
transferase (AST), alanine aminotransferase (ALT),
gamma-glutamyl transferase, albumin, and prothrombin
time. The secondary aims include improvements in liver
function (Child–Turcotte–Pugh (CTP) score, MELD
score, and chronic liver failure sequential organ failure
assessment (CLIF-SOFA)( score), changes in the
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percentage of CD34-positive cells in peripheral blood,
and changes in hepatic histological findings.
Sample size
The 1-month OS rate in patients with severe AH undergo-
ing steroid therapy has been reported as 80% and that in a
control group as 66% [7]. Moreover, the 6-month OS rate
of steroid responders has been reported as 85% and that of
non-responders as 25% [13]. A previous, large-scale, ran-
domized study compared co-administration of steroid and
pentoxifylline with steroid monotherapy. The 6-month sur-
vival rate of the complete responders in the steroid mono-
therapy group was 90.5%, whereas the 6-month survival
rate of partial responders was 82% [20]. The 2-month sur-
vival rate was 66% in the G-CSF group and 26% in the con-
trol group in a previous study conducted in patients with
hepatic failure, in whom AH was responsible for approxi-
mately 60% of cases of hepatic failure [14]. Additionally, the
2-month survival rate of null responders was 42% [21].
Based on these data, the sample size was estimated using
PASS 11.0 software (NCSS, Kaysville, UT, USA).
We hypothesized that there would be a significant dif-
ference in 6-month OS between steroid therapy and
steroid plus G-CSF therapy in patients with a PR to ste-
roids (82% vs. 90.5%). A two-sided sample size calcula-
tion with power of 0.8, significance level of 0.05, and
estimated dropout rate of 10% revealed that at least 190
patients should be included in the PR study: 95 patients
in the steroid plus placebo group and 95 in the steroid
plus G-CSF group.
We hypothesized that there would be a significant dif-
ference in 2-month OS between placebo therapy and
G-CSF therapy (42% vs. 66%) for patients with a NR to
steroids. A two-sided sample size calculation with power
of 0.8, significance level of 0.05, and estimated dropout
rate of 10% revealed that at least 78 patients should be
included in the NR study: 39 patients in the placebo
group and 39 in the G-CSF group.
Trial design
The current study is a prospective, double-blind, multi-
center (15 centers), randomized, placebo-controlled trial
with two parallel subgroups (PR and NR groups) (Fig. 1).
We will evaluate the PR (Lille score 0.16–0.56) and NR
(Lille score ≥ 0.56) by calculating the Lille score after 1
week of steroid therapy in patients who meet the eligibil-
ity criteria. Partial responders are expected to have the
OS benefits of steroid therapy, thereby, the subjects will
be randomly assigned to either the steroid-placebo
co-administration group or the steroid-G-CSF
co-administration group (1:1). Study subjects in the PR
group will be treated with prednisolone 40mg/day for
28 days followed by dose tapering.
Steroid therapy will be discontinued in the NR group
because the clinical benefits from steroid therapy are not
proven and there was concern over adverse effects of ster-
oid therapy in the NR group. When liver transplantation
is not feasible for NRs, they will be randomly assigned to
either the placebo group or the G-CSF group (1:1).
A preliminary study including five subjects each from the
steroid–G-CSF versus steroid–placebo groups in the PR
group will be conducted to assess safety data ac-
cording to the adverse event assessment criteria of
the National Marrow Donor Program (NMDP)
filgrastim-mobilized, peripheral-blood stem cell donor as-
sessment for the solid validation on the safety of
steroid-G-CSF co-administration [22]. The independent
Data Safety Monitoring Board (DSMB) committee (a
hepatologist, an oncologist, a gastroenterologist, and a
biostatistician, who do not participate in this trial) will
analyze the preliminary safety data according to the
NMDP safety assessment criteria. The data from the pre-
liminary study will be unblinded only to the DSMB com-








Data Collection at Baseline:
Demographics, medical history, 
vital signs, and blood samples
Randomization at Day 7
According to the responsiveness to 
steroid therapy (Lille score)
Partial responder 
group





Data Collection up to D180
Laboratory tests, urinalysis, AFP, liver Biopsy (D35), HVPG (D35), 
blood/body fluid sampling (D35), adverse events, mortality
Fig. 1 Flowchart for study participants. Abbreviations: G-CSF,
granulocyte colony stimulating factor; AFP, alpha-fetoprotein; HVPG,
hepatic venous pressure gradient; D, day
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results. The trial follows the recommendations for inter-
ventional trials guidelines (SPIRIT; see Additional file 1).
Interventions
All study subjects are started on corticosteroid as standard
therapy if they have no contraindications to corticosteroid
treatment (prednisolone 40mg daily); partial responders
will have their dose reduced after 28 days of administra-
tion, whereas null responders will stop the drug after 7
days administration. When oral dosing is not tolerable, 32
mg methylprednisolone will be administered via intraven-
ous injection daily, which is a dosage with equivalent effi-
cacy. G-CSF will be subcutaneously injected at a dosage of
5 μg/kg body weight daily for 5 days from the next day of
randomization in the PR and NR groups. Thereafter, it will
be administered at the same dosage every 3 days, for a
total of 12 times (days of G-CSF administration, day 8–12,
15, 18, 21, 24, 27, 30, and 33) (Fig. 2).
Study drug
G-CSF (Leucostim® Injection, Dong-A ST Co., Ltd.,
Seoul, Korea, nomenclature of component filgrastim) is
regarded as an investigational medicinal product for this
study. The dose and volume of G-CSF will be deter-
mined on the first day according to the body weight of
each subject (Table 1). G-CSF will be subcutaneously ad-
ministered 12 times (daily for 5 days, followed by every
3 days for 7 times). Normal saline (JW Pharmaceutical,
Seoul, Korea) will be used as a placebo at a maximal vol-
ume of 1.2 mL.
Inclusion criteria
The inclusion criteria are as follows:
 Age > 20 years and < 80 years
 History of clinically significant amount of alcohol
intake (≥ 50 g daily for men, and ≥ 40 g daily for
women over the last 2 months)
Fig. 2 Study schedule of enrollment, intervention, and assessment. Abbreviations: G-CSF, granulocyte colony stimulating factor; AUDIT-K, Alchol
Use Disorder Identification Test-Korea; USG, ultrasonography; CT, computed tomography; MRI, magnetic resonance imaging; CTP, Child–Turcotte–
Pugh, MELD, model for end-stage liver disease; CLIF-SOFA, chronic liver failure sequential organ failure assessment; D, day
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 MDF during the screening period = [4.6 × (patient’s
prothrombin time, sec − control prothrombin time,
sec)] + serum bilirubin level (mg/dL) ≥ 32
 New occurrence of jaundice within the last 3
months when a liver biopsy could not be performed,
(total serum bilirubin level > 5 mg/dL), or pathological
transjugular liver tissue biopsy results consistent with
alcoholic hepatitis (hepatocellular ballooning and
polymorphonuclear leukocytic infiltration)
 After satisfying criteria 1–4, Lille score > 0.16 on day 7
after daily administration of 40mg prednisolone (or
intravenous methylprednisolone at the equivalent
efficacy dose in the case of oral intolerability)
Exclusion criteria
The exclusion criteria are as follows:
 Positive for the hepatitis B surface antigen, anti-
hepatitis C antibody, or anti-human immunodefi-
ciency virus antibody
 Malignant neoplasm including hepatocellular carcinoma
 AST > 500 IU/L or ALT > 300 IU/L
 Portal vein thrombosis, hemochromatosis,
autoimmune hepatitis, Wilson’s disease, or alpha-1-
antitrypsin deficiency
 Pregnant or breastfeeding women or those who
refuse to use or cannot use contraceptives
 History of hypersensitivity to G-CSF injection
 Hypovolemic shock due to gastrointestinal bleeding
at the time of hospitalization, or in need of a
transfusion of more than three units of packed red
blood cells, or MDF elevated from < 32 points to ≥
32 points due to gastrointestinal bleeding
 Sepsis or uncontrolled acute infection
 Hepatic encephalopathy grade 3–4
 Previous history treatment with corticosteroids or
pentoxifylline within the past 3 months
 Myeloblasts observed in peripheral blood
 Severe comorbidities (type 1 hepatorenal syndrome
or serum creatinine > 2.5 mg/dL at the time of
screening, heart failure, lung disease, mental illness,
or acute pancreatitis)
 Refusal to participate in the clinical trial
Consent
The investigator will explain the details of this clinical
trial to potential study subjects, and provide sufficient
time for them to consider whether they will participate
in the study. Voluntary informed consent will be ob-
tained from the study subjects in a written form. Con-
sent will be documented as being signed and dated by
the study subject on the informed consent form. Con-
sent will be obtained in a written form from a parent or
a legal guardian or a legally acceptable representative
when a study subject is legally incompetent.
Randomization and blinding procedures
The study participants will be given a unique identifica-
tion number, and they will be assigned to either the
study-drug group or the control-placebo group.
Randomization will be conducted using a web-based
randomization program constructed by means of the
blocked randomization method. The web-based
randomization will be managed by the Medical Research
Collaborating Center of Seoul National University Hos-
pital (https://mrcc.snuh.org/) and stratification variables
are individual centers and whether or not liver biopsy
was performed.
The placebo and the study drug will be managed and
supplied by the clinical pharmacy at each institution. A
subject identification number will be given to each study
subject in accordance with the randomization table, and
the clinical pharmacy will provide the placebo or the
study drug with the study subjects and the investigators
blinded to allocation.
Safety
The principal investigator will observe adverse events
(AEs) and all AEs spontaneously reported by the study
subjects. The principal investigator will assess all AEs
for seriousness, causality, severity, and for expectedness
if the AE is related to the study drug. All AEs will be
assessed by the principal investigator as possibly, prob-
ably, or definitely related to the study drug and all ser-
ious adverse events (SAEs) that occur during the study
period will be followed until they are resolved or clearly
determined to be due to a patient’s stable or chronic
conditions or intercurrent illness. Reporting will follow
the filgrastim-mobilized, peripheral blood stem cell
donor assessment of NMDP [23].
A SAE is defined as an AE that:
 Results in death
 Results in life-threatening events
 Results in persistent or significant disability or
incapacity involving a congenital anomaly or birth
defect
Table 1 Dose of G-CSF according to the body weight of each
subject






G-CSF granulocyte colony stimulating factor
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 Represents any other important medical event that
carries a real but not a hypothetical risk of one of
the outcomes listed above
Data collection and management
An electronic clinical record form (eCRF; see Additional
file 2) will be used to collect the data on each study subject.
The study subjects will be identified on the eCRF through
their unique trial identifier, allocated at the time of recruit-
ment. Data will be coded at various stages during the study
period. Data security and storage will follow the data man-
agement plan of the Data Safety Monitoring Board
(DSMB). The DSMB plan will be developed by referring to
the guidelines of the World Health Organization [24].
Statistical analyses
Intention-to-treat analysis will be used as the main as-
sessment of efficacy. Per-protocol will be analyzed for
the primary efficacy analysis (i.e., OS), as well as to en-
sure the stability of analytical outcomes. The OS is de-
fined as the period from enrollment to death or the last
follow-up date, and will be analyzed using Kaplan–Meier
estimates. To test the difference in OS between the
G-CSF and control groups, a log-rank test will be used,
and the significance level will be 5% (two-sided test).
We will summarize the demographic and other base-
line characteristics of the study participants. Continuous
variables will be presented as mean ± standard deviations
or median (interquartile range). The two-sample t test
or Wilcoxon’s rank sum test will be used to compare the
groups according to the normal distribution. Categorical
variables will be presented as frequency and the percent-
age. Pearson’s chi-square test or Fisher’s exact test will
be used to compare the groups. Changes in the percent-
age of CD34-positive cells in peripheral blood and liver
tissues at 1 month of treatment will be compared be-
tween the groups using the two-sample t-test or Wilcox-
on’s rank sum test. In the PR group, the changes in CTP
score, MELD score, and CLIF-SOFA score at 1 week and
1, 2, 3, 4, 5, and 6 months will be compared between the
groups (steroid + placebo versus steroid + G-CSF) using
the two-sample t test or Wilcoxon’s rank sum test. In
the NR group, the changes in CTP score, MELD score,
and CLIF-SOFA score at 1 week, 1 month, and 2 months
will be compared between the groups (placebo vs.
G-CSF) using two-sample t test or Wilcoxon’s rank sum
test. In addition, repeated measures analysis of variance
(ANOVA) will be performed to analyze the difference in
repeated measures between the groups. OS of the sub-
groups according to the alcoholic hepatitis histologic
score (AHHS) will be calculated by the Kaplan–Meier
method and will be compared by log-rank test. Multi-
variate Cox regression analysis will be used to evaluate
the independent variables (P < 0.05) in the whole study
sample, the PR group, and the NR group. To determine
the mortality prediction model, the cutoff value using
area under the receiver operating characteristic curve
(AUROC) will be calculated, and sensitivity and specifi-
city will be calculated. The discrimination function of
the model will be evaluated by the Kaplan–Meier
method according to the estimated cut-off value. All
analyses will be performed using SPSS Statistics software
version 20.0 (IBM Corp., Armonk, NY, USA) and SAS
version 9.2 software (SAS Institute, Cary, NC, USA).
Discussion
The purpose of this trial is to establish proof of concept
of the efficacy of G-CSF in patients with histologically
confirmed or clinically suspected, severe AH (MDF
score ≥ 32). Patients will be screened and enrolled into
the PR (Lille score 0.16–0.56) and NR (Lille score ≥ 0.56)
groups by calculating the Lille score after 1 week of ster-
oid therapy. Steroid therapy will be discontinued in null
responders upon allocation to the NR group. They will
be randomly assigned to either the placebo group or the
G-CSF group (1:1). Partial responders are expected to
have a survival benefit from steroid therapy, thereby the
subjects will be randomly assigned to either the
steroid-placebo co-administration group or the
steroid-G-CSF co-administration group (1:1). Corticoste-
roids might reduce necroinflammation in the liver, but a
high mortality rate is still noted in patients with severe
who are AH receiving steroid therapy. Combining
G-CSF with corticosteroid treatment might promote
liver regeneration and improve neutrophil function,
leading to the amelioration of clinical outcomes.
The Korean Association for the Study of the Liver
clinical practice guidelines for the management of alco-
holic liver disease (2013) recommend liver transplant-
ation when there is no remarkable reduction in jaundice
(Lille model score ≥ 0.56) 1 week after steroid treatment
is initiated [25]. However, in addition to a shortage of
donor organs, it calls for pre-transplant 6-month abstin-
ence from alcohol as a prerequisite for liver transplant-
ation in most transplant centers; therefore, it is
practically difficult to follow the recommendation of
“considering a liver transplant” as viable.
The 6-month survival rate is higher in patients with
severe AH who are receiving pentoxifylline than in those
treated with placebo [26]. Pentoxifylline can be consid-
ered an alternative therapy for patients with severe AH
and contraindication to corticosteroid treatment [27, 28].
A previous study reported the therapeutic efficiency of
pentoxifylline in non-responders switching from cortico-
steroids [16]. Among the non-responders to corticoste-
roids, the investigators compared the 2-month survival
rate in patients in whom corticosteroids were replaced
with pentoxifylline at the early stage with that in those
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who had continuously taken corticosteroids; however, the
2-month survival rates were 35.5% and 31.0%, respectively
(P value not significant) [16]. Therefore, the switch to pen-
toxifylline is not clinically beneficial in non-responders to
corticosteroids.
It is essential to develop a new treatment modality to
overcome therapeutic refractoriness or resistance and
improve survival of patients with severe AH who are re-
fractory to steroid therapy. Some studies have reported
that G-CSF stimulates proliferation of hepatocytes in pa-
tients with alcoholic AH, cirrhosis, and liver failure, by
mobilizing CD34-positive stem cells to the liver [14, 15].
These studies enrolled a small number of subjects and
the follow-up period was only 1 month. However, they
suggest G-CSF may be beneficial in improving
long-term survival in patients with severe AH. There-
fore, we hypothesize that G-CSF treatment might pro-
long the survival of patients with severe AH who are
refractory to corticosteroid treatment. This is the first
proof-of-concept trial designed to assess the efficacy of
G-CSF according to the response to corticosteroids. This
large-scale, multicenter, randomized controlled trial is
also designed to find a special subgroup of patients in
whom G-CSF effectively works to improve liver function
and prolong survival.
Trial status
This trial is ongoing and actively recruiting. Recruitment
started on 13 May 2015. Completion is anticipated on
31 December 2020.
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